Press release - June 22nd, 2011

Cerbomed at the 4th International Epilepsy Colloquium in Marburg

ERLANGEN, Germany, 22.06.2011 – The medical device company cerbomed GmbH is proud to present NEMOS, the world’s first medical device for transcutaneous Vagus Nerve Stimulation (t-VNS), at the 4th International Epilepsy Colloquium in Marburg from June 27th to 30th. Please save June 29th and use the chance to get additional information about t-VNS in the course of a presentation at the Post-Symposium „Brain Stimulation as Treatment Option for Epilepsy”.

About NEMOS
NEMOS is the world’s first t-VNS device and is intended for people suffering from various difficult to treat neurological and psychiatric diseases. The current lead indications are drug-resistant epilepsies. NEMOS consists of a stimulation unit and an ear electrode which the patient wears like an earphone for 3 to 5 hours per day.
Cerbomed’s t-VNS therapy uses the fact that a branch of the vagus nerve is located directly under the skin in areas of the outer ear and that nerves can be stimulated through the skin (transcutaneously) with electrical impulses.

Cerbomed expects t-VNS to offer a highly attractive and cost-effective alternative to current and emerging VNS treatments, other neurostimulation methods, surgery or pharmacologic therapies. These therapeutic alternatives are connected either with higher risks or have undesirable side effects.

About cerbomed
Cerbomed is a privately held medical device company based in Erlangen, Germany, aiming to become the leader for the development of non-invasive Vagus Nerve Stimulation (VNS) therapies. The company was founded in 2005 to develop and commercialize its proprietary, transcutaneous Vagus Nerve Stimulation (t-VNS) technology and devices for therapeutic uses. NEMOS products comprise the world’s first non-invasive VNS device enabling specific electrical brain stimulation. The company has received a CE-mark for NEMOS in Europe.

pdf Download Article


Please note: NEMOS® is not cleared or approved for use in the U.S.